Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis.Food and Drug Administration (FDA) Division of Gastroenterology and Inborn Errors Products to conduct a pre-Investigational New Drug (IND) meeting to discuss development of a topical defensin-mimetic compound for the indication of induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis.
Source:
marketwired.com/press-release/cellceutix-plans-clinical-trial-in-patients-with-ulcerative-proctitis-otc-ctix-1985843.htm
Source:
marketwired.com/press-release/cellceutix-plans-clinical-trial-in-patients-with-ulcerative-proctitis-otc-ctix-1985843.htm
No comments:
Post a Comment